Date	9 November (Fri) - 10 November (Sat), 2007
Venue	Kyoto International Conference Center
Program ( Download Program )
Speakers
Reports
Photo Album

Program ( Download Program )

9 November, 2007

Time	Title	Topic	Theme	Speakers
8:55	Opening Remarks
9:00	Symposium-1	Angiogenesis, Lymphangiogenesis and Their Inhibitions	Interplay Between Tumor-derived Angiogenic Factors	Cao YH
			Novel Function of Int6/HIF2α Pathway in Neovasculization and Tumorigenesis	Shibasaki F
			Arf6 Constitutes a Central Pathway Involved in Breast Cancer Cell Invasion and Metastasis	Sabe H
			Antiangiogenic Therapy of Locally Advanced Rectal Cancer	Gasparini G
Break
11:20	Plenary Lecture-1	Cancer Prevention Frontier
Lunch Preparation
12:10	Luncheon Seminar	Molecular Mechanism of Anti-Cancer Therapies	Molecular Mechanism of Anti-Cancer Therapies	Saya H
Break
13:10	Symposium-2	Growth Factor and Growth Factor Receptors	Targeting Growth Factor Signaling for Therapeutic Benefits in Cancer Cells	Kumar R
			EGFR and HER2: Ample Opportunities for Next-Generation Cancer Therapeutics	Yarden Y
			Signaling Proteome of Breast Cancer by High Accuracy-Mass Spectrometry	Ishihama Y
			Quantitative HER2 Expression and Clinical Outcomes in Patients with Trastuzumab-Treated Metastatic Breast Cancer	Bates M
Break
15:50	Keynote Lecture-1	Application of Cell Cycle Profiling to Prediction of Recurrence and Response to Chemotherapy in Human Breast Cancers	Application of Cell Cycle Profiling to Prediction of Recurrence and Response to Chemotherapy in Human Breast Cancers	Noguchi S
16:30	Keynote Lecture-2	Cancer Therapy in The Adjuvant Setting: Issues and Perspectives	Cancer Therapy in The Adjuvant Setting: Issues and Perspectives	Gluck S
17:10	Session-1	Pharmacoeconomics of Target Therapy	The Cost-Effectiveness of Monoclonal Antibodies in the Treatment of Breast and Colorectal Cancer	Norum J
			Economic Evaluations at Gene Diagnostic Technologies and Prospect at Those Impact on Health Financing	Kondo M
Break
18:45	Music Concert	Horn Trio(Horn, Piano, Violin) : World's leading Hornist, Nobuyuki Mizuno, will play Mozart , etc.
19:30	Gala Dinner

10 November, 2007

Time	Title	Topic	Theme	Speakers
9:00	Symposium-3	Steroid Hormones and Their Manipulation	Upfront Hormonal Therapy and the Future Perspectives	Lonning P
			Development of Intracrinology and its Manipulation	Sasano H
10:10	Plenary Lecture-2	Induction of Pluripotency by Defined Factors	Induction of Pluripotency by Defined Factors	Yamanaka S
Break
11:10	OOTR Special Lecture	Ubiquitin-mediated Intracellular Protein Degradation: From Basic Mechanisms thru Human Diseases and onto Drug Targeting
Lunch
12:40	Poster Discussion
13:20	Session-2	New Therapeutic Approaches	Anticancer activity and molecular target of an NF-κB inhibitor, DHMEQ	Umezawa K
			Non-Fucosylated Antibodies as Next-Generation Therapeutic Antibodies: Mechanism of Enhanced Adcc of Non-Fucosylated Antibodies in Human Blood	Shitara K
14:10	Plenary Lecture-3	Metoronomic Chemotherapy with a Targeted Antiangiogenic Drug for Treatment of Advanced Metastatic Disease	Metoronomic Chemotherapy with a Targeted Antiangiogenic Drug for Treatment of Advanced Metastatic Disease	Kerbel R
Break
15:00	Keynote-Address
15:15	Panel Discussion
	Award Presentation
17:00	Closing Remarks

Speakers

OOTR Special Lecture by Proferssor Aaron Ciechanover Nobel Prize Laureate in Chemistry 2004 He discovered Ubiquitin-mediated Intracellular Protein Degradation.

Nadir Arber, Tel Aviv University Israel Michael Bates, Monogram Biosciences Inc. USA Yihai Cao, Karolinska Institute Sweden Louis W.C. Chow, UNIMED Medical Institute / Hong Kong University Hong Kong, SAR Aaron Ciechanover Technion-Israel Institute of Technology Israel Giampietro Gasparini, University of Rome Italy Stefan Gluck, University of Miami USA Yasushi Ishihama, Keio University Japan Robert S. Kerbel, Sunnybrook Health Sciences Centre Canada Masahide Kondo, Tsukuba University Japan Rakesh Kumar, M. D. Anderson Cancer Center USA Per Lonning, University of Bergen Norway

Shinzaburo Noguchi, Osaka University Japan Jan Norum, University Hospital of North Norway Norway Hisataka Sabe, Osaka Bio Science Institute Japan Hironobu Sasano, Tohoku University Japan Hideyuki Saya, Keio University Japan Futoshi Shibasaki, Tokyo Metropolitan Institute of Medical Science Japan Kenya Shitara, Kyowa Hakko Kogyo Co. Japan Masakazu Toi, Kyoto University Japan Kazuo Umezawa, Keio University Japan Shinya Yamanaka, Kyoto University Japan Yosef Yarden, Weizmann Institute Israel

(in alphabetical order)

Reports

9 November, 2007

Symposium-1

Dr. Cao addressed the cross-talk between vascular endothelial growth factor receptor (VEGFR)-axis and platelet-derived growth factor receptor (PDGFR) in the endothelium. He also indicated the significance of lymphangiogenesis in tumor biology. Several possible therapeutic strategies were introduced based upon these results.

Dr. Shibasaki demonstrated that the stabilization control of hypoxia-inducible factor (HIF) 2α through the tumor suppressor Int6/eIF3e is the master switch in the formation of normal neovessels. He suggested that siRNA-Int6, which could down-regulate Int6/eIF3e expression, may be useful for clinical therapy.

Dr. Gasparini introduced the phase II study of locally advanced rectal cancer. In this study, the addition of Bevacizumab, a recombinant humanized antibody against VEGF, to Capecitabine and radiotherapy was feasible and well tolerated.

Plenary Lecture-1

Dr. Arber presented several newly developed methods of screening for colorectal cancer. He also summarized some chemoprevention studies, Adenoma Prevention with Celecoxib (APC) study, Prevention of Colorectal Sporadic Adenomatous Polyps (PreSAP) study, and Adenomatous Polyp Prevention on Vioxx (APPROVe) study.

Luncheon Seminar

Dr. Saya proposed the new resistance mechanisms against chemotherapeutic agents, such as paclitaxel. He presented that dysfunction of mitotic checkpoint, treatment with anti-oxidants, and p38 inhibitor may confer resistance to the agents.

Symposium-2

Dr. Kumar said about targeting growth factor signaling for therapeutic benefits in cancer cells. This presentation was interested that the pathogenesis of epithelial cancer is influenced by the signaling cascades downstream of the human epidermal growth factor receptor family of receptor tyrosine kinase and by the HER ligands.

Dr. Ishihama said about signaling proteome of breast cancer by high-accuracy mass spectrometry. This presentation was interested in the influence of estradiol treatment on the time-resolved phosphorylation of proteins belonging to EGFR signaling pathway.

Dr. Bates said about quantitative HER2 expression and clinical outcomes in patients with trastuzumab-treated metastatic breast cancer. This presentation was interested that their data confirm prior observations of a continuum of trastuzumab responsiveness related to quantitative amount of HER2 expression or homodimers as measured by VeraTag.

Keynote Lecture-2

Dr. Gluck said about neoadjuvant therapy in breast cancer. This presentation was interested in showing recently study about neoadjuvant therapy and new combination therapy.

Session-1

Dr. Norum talked about the cost-effectiveness of trastuzumab in adjuvant breast cancer therapy in Norway. In metastatic setting, the figure is around frequently employed cut-off levels. In metastatic colorectal cancer there are no solid data on cetuximab or bevacizumab indication the cost per life year gained being less than accepted limits.

Dr. Kondo presented economic evaluations of a recently developed gene diagnostic technology, 21-gene signature of breast cancer, and its impact on health financing.

10 November, 2007

Symposium-3

Dr. Lonning addressed several important questions concerning hormonal therapy, current trials for premenopausals using combined treatment with an LH-RH analogue and an aromatase inhibitor, optimal use of aromatase inhibitor for postmenopausals, and optimal duration of therapy.

Dr. Sasano focused on the importance of the development of new modes of endocrine therapy based on “intracrine” concepts. Not only aromatase inhibitors, but also other enzymes such as 17β-hydroxysteroid dehydrogenase (17β-HSD) isozymes, estrogen sulfatase (STS), and estrogen sulfotransferase, play pivotal roles in endocrine therapy of postmenopausal breast cancer patients.

Session-2

Dr. Umezawa presented anticancer activity and molecular target of a NK-κB inhibitor, dehydroxymethyleproxyquinomicin (DHMEQ). He also mentioned resistomycin and 9-methylstreptimidone as new NF-κB inhibitors.

Plenary Lectur-3

Dr. Kerbel presented metronomic chemotherapy combined with an antiangiogenic drug, such as bevacizumab, moved into phase Ⅱ clinical trial. He also showed that combination chemotherapy using cyclophosphamide and UFT might be particularly promising for metronomic chemotherapy in these indications.

Photo Album

Kyoto International Conference Center

direction board

poster discussion

panel discussion